Clinical Trials
3
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
Phase 1
Active, not recruiting
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Michael Choi
- Target Recruit Count
- 24
- Registration Number
- NCT03422393
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL
Phase 1
Terminated
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Michael Choi
- Target Recruit Count
- 2
- Registration Number
- NCT02784834
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
Phase 1
Withdrawn
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Michael Choi
- Registration Number
- NCT02611908
News
No news found